Baltic Network against life-treatening viral infections

Formerly the New Visby Hepatitis C Network

  • Increase font size
  • Default font size
  • Decrease font size

6th Tallinn 2009

6th ANNUAL MEETING OF THE NEW VISBY UNIVERSITY NETWORK ON HEPATITIS C, TALLINN, ESTONIA, February 8-11, 2009

Sunday, February 8

Venue: Reval Hotel Central, Conference room
9.45-12.00 Preparation of joint reports
12.00-13.00 Lunch
13.00-16.00 Discussion on future Network activities

Monday, February 9

Venue: Meeting will take place at National Institute for Health Development, Hiiu 42, Tallinn
Language: The meeting language is English

9.00-9.30 - Registration

9.30-9.45 - Opening of the meeting

Toomas Veidebaum, Director of Research Centre, National Institute for Health Development, Tallinn

9.45-12.00 Immune response against HCV

9.45-10.15  Helmut Diepolder. University of Munich, Germany
Hepatitis C virus specific regulatory T cells during acute and chronic hepatitis C virus infection (30min)

10.15-10.45 Yves Rivière. Institut Pasteur, Paris, France
HCV-specific immune responses in uninfected individuals with no known risk for HCV exposition (30min)

10.45-11.15 - Coffee & tea break

11.15-11.40 Leonid Titov. Research Institute for Epidemiology & Microbiology, Minsk, Belarus
Molecular-genetic characterization of the variable regions of anti-HCV antibodies (25min)

11.40-12.00 Elena Tzyganova. Moscow State University of Medicine and Dentistry, Russia
Occult hepatitis C among cases of acute hepatitis of unknown origin (20min)

12.00-13.10 HCV infection: course and treatment

12.00-12.25 Riina Salupere. University of Tartu, Estonia
Extrahepatic manifestations associated with hepatitis C virus infection (25min)

12.25-12.45 Olga Znoyko. Moscow State University of Medicine and Dentistry,Russia
Viral hepatitis C: resistance to interferon as a phenomenon and as a problem (20min)

12.45-13.10 Vadim Brjalin. West Tallinn Central Hospital, University of Tartu, Estonia
Treatment of HCV patients in Estonia (25min)

13.10-14.30  Lunch

14.30-15.30 HCV infection: course and treatment: experimental approaches

14.30-15.00 Alex Ivanov. Engelhardt Institute of Molecular Biology, Moscow, Russia
New inhibitors of HCV and HIV replication (30min)

15.00-15.30 Andrei Nikonov. University of Tartu, Estonia
Control of Hepatitis C Virus RNA-dependent RNA polymerase activity via fingers domain (30min)

15.30-17.30 Control and diagnostics of viral infections

15.30-16.00 Anders Widell. Lund University, Malmö, Sweden
HCV genotyping using a Luminex based assay (30min)

16.00-16.30 Coffee & tea break

16.30-16.50 Ann-Sofie Månsson. Lund University, Malmö, Sweden
Analysis of nosocomial hepatitis C -having access to the right sample (20min)

16.50-17.10 Olga Gorskaya. Research Institute of Obstetrics and Gynecology, St.- Petersburg, Russia
The problems of detection hepatitis C RNA in donor blood by PCR (20min)

17.10-17.30 Hanna Lilja Gudjunsdottir. Lund University, Malmö, Sweden
Parvovirus 4 findings in Sweden and Iceland - an update (20min)

19.30 -Dinner

Tuesday, February 10

9.30-11.20 Molecular epidemiology

9.30-10.00 Kristi Rüütel. National Institute for Health Development, Tallinn, Estonia
HIV epidemiology in Estonia (30min)

10.00-10.30 Tatjana Tallo. National Institute for Health Development, Tallinn, Estonia
Epidemiology and molecular epidemiology of hepatitis A, B and C in Estonia (30min)

10.30-11.00 Helene Norder. Swedish Institute for Infectious Disease Control, Stockholm, Sweden
Molecular epidemiology of hepatitis C in Russia and the Baltic Region (30min)

11.00-11.20 Vladimir Eremin. Research Institute for Epidemiology & Microbiology, Minsk, Belarus
Molecular epidemiology of HCV infection in Belarus (20min)

11.20-11.50 Coffee & tea break

11.50-13.10 Viral vaccines

11.50-12.30 Maria Isaguliants. Swedish Institute for Infectious Disease Control, Stockholm, Sweden
DNA vaccines against chronic viral infections (40min)

12.30-13.10 Matti Sallberg. Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
Antiviral effects of therapeutic DNA vaccination in patients with chronic hepatitis C (40min)

13.10-14.10 Lunch

14.10-16.00 Basic virology

14.10-14.50 Birke Bartosch. INSERM U871, France
Receptor complementation and targeted mutagenesis reveal SR-BI as essential HCV cell entry co-factor and functionally imply its ectodomain and cytoplasmic tail (40min)

14.50-15.30 Jens Bukh. Copenhagen University Hospital, Hvidovre and University of Copenhagen, Denmark
JFH1-based cell culture systems for hepatitis C virus. Copenhagen Hepatitis C Program (CO-HEP) (40min)

15.30-16.00 Juris Jansons. Latvian Biomedical Research and Study Centre, Riga, Latvia & Lund University, Malmö, Sweden & Natalia Petrakova. Ivanovsky Institute of Virology, Moscow & Lund University, Malmö, Sweden HCV 1b and 3a pseudoviral particles: design and neutralization by sera of acute hepatitis C patients with relation to infection outcome (15min+15min)

16.00-16.30 Coffee & tea break

16.30- Visit to Department of Virology, National Institute for Health Development (optional)

Wednesday, February 11

9.00-11.00 Discussion and planning of future activity of the “New VISBY University Network on Hepatitis C”
11.00-11.30 Coffee break
11.30-13.30 Preparation for coming application